- Poster presentation
- Open access
- Published:
Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
Cancer & Metabolism volume 2, Article number: P19 (2014)
Background
Cancer anorexia-cachexia is a frequent, debilitating and life-threatening condition in which altered metabolism and reduced food intake contribute to weight loss (mainly due to lean body mass [LBM] loss), which cannot be reverted by conventional nutritional support. Safe/effective treatments for cancer cachexia remain an unmet need. The hunger hormone ghrelin has been shown to activate key pathways in the regulation of body composition. Anamorelin (ANAM) is a novel, selective, oral ghrelin receptor agonist with appetite-enhancing and anabolic activity. Anamorelin is currently being investigated in phase III studies for the treatment of anorexia-cachexia in advanced non-small cell lung cancer (also known as the ROMANA program).
Material and Methods
Eighty-two patients with advanced cancer, ECOG performance score ≤ 2 and weight loss 5% within prior 6 months were treated with placebo (n=36) or 50mg anamorelin (n=38) once daily for 12 weeks. Body composition by DXA, handgrip strength (HGS) and Quality of Life (QoL; ASAS scale) were assessed at baseline, 4, 8 and 12 weeks. Solid tumors represented prevalent malignancy (>93%) with no difference in cancer types between treatment groups.
Results
Treatment with anamorelin for 12 weeks significantly increased total body mass (TBM) and LBM. Increases in LBM and TBM in anamorelin-treated patients were strongly correlated (r2=0.7249, p< 0.0001). Anamorelin treatment improvements in HGS and QoL were previously presented [1]. Anamorelin was well tolerated, and types and prevalence of AEs were similar between treatment arms.
Conclusion
Decreased body weight and LBM are poor prognostic factors in cancer cachexia patients. This study demonstrates that 50mg anamorelin treatment for 12 weeks significantly increased LBM, which largely contributed to the increases in total body mass. Together with its appetite-enhancing activity, these results support the further development of anamorelin in treating cancer anorexia-cachexia.
References
Garcia JM, Yan Y, Manning Duus E, Friend J: Anamorelin’s effects on appendicular lean body mass in cancer patients with cachexia; results from a phase II randomized, double blind, multicenter study. Annals of Oncology. 2012, 23 (Suppl 9): ix512-
Author information
Authors and Affiliations
Rights and permissions
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Garcia, J.M., Yan, Y., Manning-Duus, E. et al. Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study. Cancer Metab 2 (Suppl 1), P19 (2014). https://doi.org/10.1186/2049-3002-2-S1-P19
Published:
DOI: https://doi.org/10.1186/2049-3002-2-S1-P19